Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells
Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5...
Gespeichert in:
Veröffentlicht in: | Cancer research (Chicago, Ill.) Ill.), 1987-08, Vol.47 (15), p.4208-4212 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 4212 |
---|---|
container_issue | 15 |
container_start_page | 4208 |
container_title | Cancer research (Chicago, Ill.) |
container_volume | 47 |
creator | MARCUS, S. L DUTCHER, J. P PAIETTA, E CIOBANU, N STRAUMAN, J WIERNIK, P. H HUTNER, S. H FRANK, O BAKER, H |
description | Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level. |
format | Article |
fullrecord | <record><control><sourceid>pubmed_pasca</sourceid><recordid>TN_cdi_pubmed_primary_3496958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3496958</sourcerecordid><originalsourceid>FETCH-LOGICAL-h184t-a71dc9b31656d8f44a993e0efb62ef3235c84a74223617df10e461c7dcd2c0243</originalsourceid><addsrcrecordid>eNo9kMtKxDAYhYMo4zj6CMK_cFtobm26lMEbDLhQ10Mm-TuNpk1J0pF5CN_ZgoOrw8d3OItzRpZUclXUQshzsizLUhVS1OySXKX0OaOkpVyQBRdN1Ui1JD9veMCI0B3HcHBZ924IySVYQzBmitENe9AJcocQMU0-Q2hB2zBmd0BwfT8NYZZRj0f4drmDzu27woY0yyFj9Dh9uQEY6MGCP_ZjF2bGQpt5QGe08OW8xwgGvU_X5KLVPuHNKVfk4_Hhff1cbF6fXtb3m6KjSuRC19SaZsdpJSurWiF003Assd1VDFvOuDRK6Fowxita25aWKCpqamssMyUTfEVu_3bHadej3Y7R9Toet6dbZn938joZ7duoB-PSf03xSikl-S8Pr2_O</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>MARCUS, S. L ; DUTCHER, J. P ; PAIETTA, E ; CIOBANU, N ; STRAUMAN, J ; WIERNIK, P. H ; HUTNER, S. H ; FRANK, O ; BAKER, H</creator><creatorcontrib>MARCUS, S. L ; DUTCHER, J. P ; PAIETTA, E ; CIOBANU, N ; STRAUMAN, J ; WIERNIK, P. H ; HUTNER, S. H ; FRANK, O ; BAKER, H</creatorcontrib><description>Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.</description><identifier>ISSN: 0008-5472</identifier><identifier>EISSN: 1538-7445</identifier><identifier>PMID: 3496958</identifier><identifier>CODEN: CNREA8</identifier><language>eng</language><publisher>Philadelphia, PA: American Association for Cancer Research</publisher><subject>Adult ; Ascorbic Acid - blood ; Evaluation Studies as Topic ; Female ; Humans ; Immunization, Passive - adverse effects ; Immunotherapy - adverse effects ; Interleukin-2 - adverse effects ; Interleukin-2 - therapeutic use ; Killer Cells, Natural - immunology ; Killer Cells, Natural - transplantation ; Male ; Middle Aged ; Neoplasms - blood ; Neoplasms - therapy ; Pantothenic Acid - blood ; Scurvy - blood ; Scurvy - etiology ; Vitamin E - blood</subject><ispartof>Cancer research (Chicago, Ill.), 1987-08, Vol.47 (15), p.4208-4212</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8368885$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3496958$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MARCUS, S. L</creatorcontrib><creatorcontrib>DUTCHER, J. P</creatorcontrib><creatorcontrib>PAIETTA, E</creatorcontrib><creatorcontrib>CIOBANU, N</creatorcontrib><creatorcontrib>STRAUMAN, J</creatorcontrib><creatorcontrib>WIERNIK, P. H</creatorcontrib><creatorcontrib>HUTNER, S. H</creatorcontrib><creatorcontrib>FRANK, O</creatorcontrib><creatorcontrib>BAKER, H</creatorcontrib><title>Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells</title><title>Cancer research (Chicago, Ill.)</title><addtitle>Cancer Res</addtitle><description>Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.</description><subject>Adult</subject><subject>Ascorbic Acid - blood</subject><subject>Evaluation Studies as Topic</subject><subject>Female</subject><subject>Humans</subject><subject>Immunization, Passive - adverse effects</subject><subject>Immunotherapy - adverse effects</subject><subject>Interleukin-2 - adverse effects</subject><subject>Interleukin-2 - therapeutic use</subject><subject>Killer Cells, Natural - immunology</subject><subject>Killer Cells, Natural - transplantation</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - therapy</subject><subject>Pantothenic Acid - blood</subject><subject>Scurvy - blood</subject><subject>Scurvy - etiology</subject><subject>Vitamin E - blood</subject><issn>0008-5472</issn><issn>1538-7445</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1987</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kMtKxDAYhYMo4zj6CMK_cFtobm26lMEbDLhQ10Mm-TuNpk1J0pF5CN_ZgoOrw8d3OItzRpZUclXUQshzsizLUhVS1OySXKX0OaOkpVyQBRdN1Ui1JD9veMCI0B3HcHBZ924IySVYQzBmitENe9AJcocQMU0-Q2hB2zBmd0BwfT8NYZZRj0f4drmDzu27woY0yyFj9Dh9uQEY6MGCP_ZjF2bGQpt5QGe08OW8xwgGvU_X5KLVPuHNKVfk4_Hhff1cbF6fXtb3m6KjSuRC19SaZsdpJSurWiF003Assd1VDFvOuDRK6Fowxita25aWKCpqamssMyUTfEVu_3bHadej3Y7R9Toet6dbZn938joZ7duoB-PSf03xSikl-S8Pr2_O</recordid><startdate>19870801</startdate><enddate>19870801</enddate><creator>MARCUS, S. L</creator><creator>DUTCHER, J. P</creator><creator>PAIETTA, E</creator><creator>CIOBANU, N</creator><creator>STRAUMAN, J</creator><creator>WIERNIK, P. H</creator><creator>HUTNER, S. H</creator><creator>FRANK, O</creator><creator>BAKER, H</creator><general>American Association for Cancer Research</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>19870801</creationdate><title>Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells</title><author>MARCUS, S. L ; DUTCHER, J. P ; PAIETTA, E ; CIOBANU, N ; STRAUMAN, J ; WIERNIK, P. H ; HUTNER, S. H ; FRANK, O ; BAKER, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-h184t-a71dc9b31656d8f44a993e0efb62ef3235c84a74223617df10e461c7dcd2c0243</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1987</creationdate><topic>Adult</topic><topic>Ascorbic Acid - blood</topic><topic>Evaluation Studies as Topic</topic><topic>Female</topic><topic>Humans</topic><topic>Immunization, Passive - adverse effects</topic><topic>Immunotherapy - adverse effects</topic><topic>Interleukin-2 - adverse effects</topic><topic>Interleukin-2 - therapeutic use</topic><topic>Killer Cells, Natural - immunology</topic><topic>Killer Cells, Natural - transplantation</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - therapy</topic><topic>Pantothenic Acid - blood</topic><topic>Scurvy - blood</topic><topic>Scurvy - etiology</topic><topic>Vitamin E - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MARCUS, S. L</creatorcontrib><creatorcontrib>DUTCHER, J. P</creatorcontrib><creatorcontrib>PAIETTA, E</creatorcontrib><creatorcontrib>CIOBANU, N</creatorcontrib><creatorcontrib>STRAUMAN, J</creatorcontrib><creatorcontrib>WIERNIK, P. H</creatorcontrib><creatorcontrib>HUTNER, S. H</creatorcontrib><creatorcontrib>FRANK, O</creatorcontrib><creatorcontrib>BAKER, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Cancer research (Chicago, Ill.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MARCUS, S. L</au><au>DUTCHER, J. P</au><au>PAIETTA, E</au><au>CIOBANU, N</au><au>STRAUMAN, J</au><au>WIERNIK, P. H</au><au>HUTNER, S. H</au><au>FRANK, O</au><au>BAKER, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells</atitle><jtitle>Cancer research (Chicago, Ill.)</jtitle><addtitle>Cancer Res</addtitle><date>1987-08-01</date><risdate>1987</risdate><volume>47</volume><issue>15</issue><spage>4208</spage><epage>4212</epage><pages>4208-4212</pages><issn>0008-5472</issn><eissn>1538-7445</eissn><coden>CNREA8</coden><abstract>Adoptive immunotherapy of human cancer was investigated in our institution as part of a National Cancer Institute extramural group study. This treatment, for patients with metastatic malignant melanoma, hypernephroma, and colon carcinoma, consisted of three phases: (a) 5 days of i.v. high-dose (10(5) units/kg every 8 h) interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and (c) 4 days of high-dose interleukin 2 plus three infusions of autologous lymphokine-activated killer cells. Toxicities included fever, chills, tachycardia, hypotension, vomiting, diarrhea, and fluid retention. Ascorbic acid is known to be important to cell-mediated immunity, and it has been reported to be depleted during physiologically stressful events. Therefore, we determined plasma ascorbic acid levels in patients (n = 11) before adoptive immunotherapy and before and after Phases 1, 2, and 3 of treatment. Patients entering the trial were not malnourished. Mean plasma ascorbic acid levels were normal (0.64 +/- 0.25 mg/dl) before therapy. Mean levels dropped by 80% after the first phase of treatment with high-dose interleukin 2 alone (0.13 +/- 0.08 mg/dl). Mean plasma ascorbic acid levels remained severely depleted (0.08 to 0.13 mg/dl) throughout the remainder of the treatment, becoming undetectable (less than 0.05 mg/dl) in eight of 11 patients during this time. Values obtained from 24-h urine collections on two of two patients indicated that ascorbate was not excreted in the urine. Plasma ascorbic acid normalized in three of three patients tested 1 mo after the completion of treatment. Unlike the results for ascorbic acid, blood pantothenate and plasma vitamin E remained within normal limits in all 11 patients throughout the phases of therapy. Responders (n = 3) differed from nonresponders (n = 8) in that plasma ascorbate levels in the former recovered to at least 0.1 mg/dl (frank clinical scurvy) during Phases 2 and 3, whereas levels in the latter fell below this level.</abstract><cop>Philadelphia, PA</cop><pub>American Association for Cancer Research</pub><pmid>3496958</pmid><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0008-5472 |
ispartof | Cancer research (Chicago, Ill.), 1987-08, Vol.47 (15), p.4208-4212 |
issn | 0008-5472 1538-7445 |
language | eng |
recordid | cdi_pubmed_primary_3496958 |
source | MEDLINE; American Association for Cancer Research; EZB-FREE-00999 freely available EZB journals |
subjects | Adult Ascorbic Acid - blood Evaluation Studies as Topic Female Humans Immunization, Passive - adverse effects Immunotherapy - adverse effects Interleukin-2 - adverse effects Interleukin-2 - therapeutic use Killer Cells, Natural - immunology Killer Cells, Natural - transplantation Male Middle Aged Neoplasms - blood Neoplasms - therapy Pantothenic Acid - blood Scurvy - blood Scurvy - etiology Vitamin E - blood |
title | Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A36%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_pasca&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Severe%20hypovitaminosis%20C%20occurring%20as%20the%20result%20of%20adoptive%20immunotherapy%20with%20high-dose%20interleukin%202%20and%20lymphokine-activated%20killer%20cells&rft.jtitle=Cancer%20research%20(Chicago,%20Ill.)&rft.au=MARCUS,%20S.%20L&rft.date=1987-08-01&rft.volume=47&rft.issue=15&rft.spage=4208&rft.epage=4212&rft.pages=4208-4212&rft.issn=0008-5472&rft.eissn=1538-7445&rft.coden=CNREA8&rft_id=info:doi/&rft_dat=%3Cpubmed_pasca%3E3496958%3C/pubmed_pasca%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/3496958&rfr_iscdi=true |